

Technology Advisory Committee B Interests Register

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

[Review of TA658] [ID4067]

Publication Date: TBC.

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
Peter Wheatley Price	TAC B Committee Member	Direct	Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505). We have just successfully exited the CDF (ID1635)	12/12/2023	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
Neil Rabin	Clinical Expert	Direct – Financial	<p>Celgene (BMS). Support to attend conferences, speak at educational meetings and advisory boards.</p> <p>Janssen-Cilag. Support to attend conferences, speak at educational meetings and advisory boards.</p> <p>Takeda. Support to attend conferences and advisory boards.</p> <p>Sanofi. Advisory board.</p>	<p>14/03/2024</p> <p>17/01/2024</p>	It was agreed that Neil's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			Menarini Stemline Oncology. Advisory board. Amgen. Advisory board.		
Caroline Donoghue	Patient Expert	Indirect - Financial	We have received funding from the manufacturer of the technology in the last 12 months (£48,980) In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies.	14/03/2024 17/01/2024	It was agreed that Caroline's declaration would not prevent her from participating in discussions on this appraisal.
Jonathan Sive	Clinical Expert	Indirect - Financial	We have received funding from the manufacturer of the technology in the last 12 months (£48,980). In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).	14/03/2024 17/01/2024	It was agreed that Jonathan's declaration would not prevent him from participating in discussions on this appraisal.
Jonathan Sive	Clinical Expert	Direct - Financial	Education grant from Janssen for virtual attendance at 2023 meeting of American Society for Haematology (£826)	14/03/2024 17/01/2024	It was agreed that Jonathan's declaration would not prevent him from participating in discussions on this appraisal.

